Stanford researchers, led by Bali Pulendran, reported a preclinical intranasal vaccine that elicited broad mucosal protection in mice against multiple respiratory viruses (including SARS‑CoV‑2), bacterial pathogens and house‑dust‑mite allergen. Published in Science, the work demonstrates a vaccination strategy that stimulates both innate and adaptive mucosal immunity and produced durable lung protection for several months in animal models. The authors emphasize the data are preclinical and that translation to humans will require careful safety and efficacy testing; mucosal vaccines aim to create local immunity at the site of pathogen entry rather than systemic-only responses.